Negative Serology by Immunoenzymatic Test (EIA) in HIV-infected Children Treated Early With Antiretroviral in the ANRS-Pediacam Study: Pathophysiological Mechanisms

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The objective of the study is to identify the pathophysiological mechanisms responsible for the induction and maintenance of negative serologies by EIA tests in HIV-infected children treated early with HAART in the ANRS 12225-Pediacam III cohort in Cameroon The hypothesis of better control of HIV infection through interactions between immunological, viral, and genetic factors was made to build the following objectives: * Immunological aspect: lack of humoral response or immune activation * Virological aspect: Reduced HIV reservoir size * Determine the HLA phenotype in the different groups of children included and the KIR genotypes.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: t
View:

⁃ Case control study

• Children included and followed in the ANRS 12225 study - Pediacam III

• Having plasma samples in the bio bank during the above-mentioned periods Case:children with at least one negative HIV serology made by ELISA, permanent or transientduring follow-up.

⁃ Control (4 groups)

• HIV-infected children with positive serology and viral load (VL) \<400 copies /ml

• HIV-infected children with positive serology and VL ≥400 copies / ml

• HIV-uninfected children born to HIV-positive mothers

• HIV-uninfected children born to HIV-uninfected mothers Selection of cases and controls will be matched on gestational age (premature \<37, term ≥37 weeks) and year of birth (2007-2008 and 2009-2010).

⁃ Cross sectional study Inclusion criteria

• All children still followed in the ANRS - Pediacam III cohort

• Written consent of one of the parents or the guardian and assent of the child if aged ≥ 11 years and complete disclosure of HIV statusfor infected children for participation to the study.

Locations
Other Locations
Cameroon
Hôpital de Jour - Hôpital Laquintinie de Douala
NOT_YET_RECRUITING
Douala
Service de Pédiatrie - Centre Hospitalier d'Essos
RECRUITING
Yaoundé
Unité Pédiatrique de Jour - Centre Mère et Enfant de la Fondation Chantal Biya
RECRUITING
Yaoundé
Contact Information
Primary
Mathurin C Tejiokem, Doctor
tejiokem@pasteur-yaounde.org
00237222231803
Backup
Albert Faye, Doctor
albert.faye@rdb.ap-hop-paris.fr
0033140035361
Time Frame
Start Date: 2024-05-02
Estimated Completion Date: 2025-08-30
Participants
Target number of participants: 451
Treatments
Other: Children enrolled in Pediacam III ANRS12225 cohort
Related Therapeutic Areas
Sponsors
Collaborators: Hospital General De Douala, Centre Hospitalier D'essos, Centre Mère et Enfant de la Fondation Chantal Biya, Centre Pasteur du Cameroun, Université Paris-Sud, Hopital Universitaire Robert-Debre, CH Orléans, Institut Pasteur
Leads: ANRS, Emerging Infectious Diseases

This content was sourced from clinicaltrials.gov